AbsciABSI
About: Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
Employees: 157
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
121% more call options, than puts
Call options by funds: $850K | Put options by funds: $384K
55% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 22
27% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 33
7% more funds holding
Funds holding: 122 [Q3] → 131 (+9) [Q4]
0.52% more ownership
Funds ownership: 63.79% [Q3] → 64.31% (+0.52%) [Q4]
30% less capital invested
Capital invested by funds: $277M [Q3] → $194M (-$83.2M) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Guggenheim Vamil Divan 35% 1-year accuracy 9 / 26 met price target | 317%upside $10 | Buy Reiterated | 20 Mar 2025 |
Needham Gil Blum 7% 1-year accuracy 12 / 162 met price target | 275%upside $9 | Buy Reiterated | 19 Mar 2025 |
HC Wainwright & Co. Swayampakula Ramakanth 22% 1-year accuracy 45 / 203 met price target | 192%upside $7 | Buy Reiterated | 19 Mar 2025 |
Keybanc Scott Schoenhaus 26% 1-year accuracy 8 / 31 met price target | 108%upside $5 | Overweight Maintained | 8 Jan 2025 |
Financial journalist opinion
Based on 8 articles about ABSI published over the past 30 days









